Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Glioblastoma: early-phase trial registry
78 of 200 indexed Glioblastoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #49 of 28,707 conditions by registered trial count.
200 US clinical trials · 78 currently recruiting · #49 of 28,707 conditions by registered trial count
Glioblastoma: 200 US clinical trials tracked, 78 recruiting.
Glioblastoma is the subject of 200 registered US clinical trials on ClinicalTrials.gov, 78 of them currently open to new participants. 15 are in Phase 3-4 (later-stage) and 148 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 10 of these trials.
Enrollment posture brief
Registry condition glioblastoma
OPEN 78 | RECR 39% | LATE 15 | EARLY 148 | RANK #49 | SPON 10
Volume-matched condition peers
Nearest open-share peer: Chronic Myeloid Leukemia (39% recruiting · 36 trials)
Glioblastoma lists 78 open slots (39% of 200 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Glioblastoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Glioblastoma recruits in line with its size-band peers.
78 of 200 indexed trials (39%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Glioblastoma trials is spread across many organizations.
National Cancer Institute (NCI) accounts for 10 of 200 trials (5%). 112 distinct sponsors appear on at least one study for this condition label.
-
Most Glioblastoma trials plan to enrol fewer than 100 people.
Median target enrolment is 44 among the 200 trials that report a genuine target (sentinel values excluded). 153 of those (76.5%) plan for fewer than 100 participants.
-
Glioblastoma research is mostly interventional.
186 interventional and 14 observational studies make up this index (93% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
200 total, page 4 of 4
Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Washington University School of Medicine
NCT04015700
A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
In8bio
NCT05664243
Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma
John Flickinger
NCT04019262
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
Hoffmann-La Roche
NCT00943826
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status
EMD Serono
NCT00689221
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
Genentech
NCT01598597
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
Celgene
NCT01421524
A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1
Denovo Biopharma
NCT03776071
Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma
Ludwig Institute for Cancer Research
NCT02336165
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
National Cancer Institute (NCI)
NCT01609790
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
Celldex Therapeutics
NCT01498328
Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas
Duke University
NCT00597402
A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm
Incuron
NCT01905228
Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)
M.D. Anderson Cancer Center
NCT01067469
Pembrolizumab +/- Bevacizumab for Recurrent GBM
Dana-Farber Cancer Institute
NCT02337491
Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG
Annick Desjardins
NCT00613132
Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma
National Cancer Institute (NCI)
NCT01849146
Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma
University of California, San Francisco
NCT00525525
Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas
Katy Peters
NCT00610571
Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma
Diffusion Pharmaceuticals
NCT01465347
PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma
Massachusetts General Hospital
NCT01112527
Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma
Duke University
NCT00611325
Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma
Jonsson Comprehensive Cancer Center
NCT01149850
PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas
Duke University
NCT00612651
Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma
Massachusetts General Hospital
NCT03139916
Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102
Alaunos Therapeutics
NCT03679754
TH-302 in Combination With Bevacizumab for Glioblastoma
The University of Texas Health Science Center at San Antonio
NCT02342379
A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma
H. Lee Moffitt Cancer Center and Research Institute
NCT00606008
Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors
National Institute of Neurological Disorders and Stroke (NINDS)
NCT00088400
Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma
ImmunityBio
NCT02014844
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma
Istari Oncology
NCT04479241
Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme
Dana-Farber Cancer Institute
NCT00165477
A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma
Tracon Pharmaceuticals
NCT01564914
Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide
Washington University School of Medicine
NCT01907165
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption
InSightec
NCT03551249
A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma
H. Lee Moffitt Cancer Center and Research Institute
NCT00762255
Biomarkers for Prognosis of Glioblastoma (GBM)
University of Nebraska
NCT01493219
A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)
Children's Hospital Medical Center, Cincinnati
NCT03355794
Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma
The Cooper Health System
NCT04552886
Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma
Dana-Farber Cancer Institute
NCT02478164
Study of the Safety and Efficacy of Dichloroacetate (DCA) in Glioblastoma and Other Recurrent Brain Tumors
University of Florida
NCT01111097
ASP8374 + Cemiplimab in Recurrent Glioma
Dana-Farber Cancer Institute
NCT04826393
Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma
Icahn School of Medicine at Mount Sinai
NCT03341806
BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab
Seema Nagpal
NCT03020602
Feasibility Study of Modified Atkins Ketogenic Diet in the Treatment of Newly Diagnosed Malignant Glioma
University of Cincinnati
NCT03278249
Accurate DCE-MRI Measurement of Glioblastoma Using Point-of-care Portable Perfusion Phantom
University of Alabama at Birmingham
NCT05140902
Palliative 4pi Radiotherapy in Treating Patients With Recurrent Glioblastoma Multiforme
Jonsson Comprehensive Cancer Center
NCT02575027
Tivozanib for Recurrent Glioblastoma
Massachusetts General Hospital
NCT01846871
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
City of Hope Medical Center
NCT01082926
A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma
Emory University
NCT02157103
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 87 |
| Phase 2 | 61 |
| Phase 3 | 13 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Glioblastoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Glioblastoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Glioblastoma page
200 registered trials, 78 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 78 Glioblastoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Glioblastoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Glioblastoma condition card totals 200 registered trials; most-linked intervention Temozolomide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.